- Home
- MYGN vs TRC Comparison
MYGN vs TRC Comparison
Compare MYGN & TRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TRC
- Stock Information
- Founded
- MYGN 1991
- TRC 1843
- Country
- MYGN United States
- TRC United States
- Employees
- MYGN N/A
- TRC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TRC Real Estate
- Sector
- MYGN Health Care
- TRC Finance
- Exchange
- MYGN Nasdaq
- TRC Nasdaq
- Market Cap
- MYGN 423.1M
- TRC 485.7M
- IPO Year
- MYGN 1995
- TRC N/A
- Fundamental
- Price
- MYGN $7.64
- TRC $16.81
- Analyst Decision
- MYGN Hold
- TRC
- Analyst Count
- MYGN 13
- TRC 0
- Target Price
- MYGN $13.50
- TRC N/A
- AVG Volume (30 Days)
- MYGN 1.4M
- TRC 104.8K
- Earning Date
- MYGN 11-06-2025
- TRC 11-06-2025
- Dividend Yield
- MYGN N/A
- TRC N/A
- EPS Growth
- MYGN N/A
- TRC N/A
- EPS
- MYGN N/A
- TRC N/A
- Revenue
- MYGN $832,900,000.00
- TRC $45,307,000.00
- Revenue This Year
- MYGN $0.17
- TRC N/A
- Revenue Next Year
- MYGN $6.19
- TRC N/A
- P/E Ratio
- MYGN N/A
- TRC N/A
- Revenue Growth
- MYGN 3.83
- TRC 14.79
- 52 Week Low
- MYGN $3.76
- TRC $14.71
- 52 Week High
- MYGN $29.30
- TRC $19.39
- Technical
- Relative Strength Index (RSI)
- MYGN 75.45
- TRC 41.85
- Support Level
- MYGN $6.73
- TRC $16.49
- Resistance Level
- MYGN $7.05
- TRC $16.97
- Average True Range (ATR)
- MYGN 0.38
- TRC 0.33
- MACD
- MYGN 0.10
- TRC -0.02
- Stochastic Oscillator
- MYGN 94.31
- TRC 32.17
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.